Welcome to our dedicated page for China Pharma news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma stock.
China Pharma Holdings, Inc. reports developments tied to its specialty pharmaceutical business in China, where it develops, manufactures, and markets products for cardiovascular, central nervous system, infectious, and digestive diseases. News commonly centers on its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., product portfolio updates, NMPA-related approvals, and dosage forms that include tablets, capsules, injectables, oral solutions, and other pharmaceutical products.
Company updates also cover the dry eye disease therapeutic device, completed generic-drug consistency evaluation for candesartan tablets, financing arrangements, convertible-note redemptions, and common-stock reverse splits. These announcements connect operating product activity with capital-structure actions for CPHI's NYSE American-listed common stock.
China Pharma Holdings, Inc. (CPHI) reported a 46.8% revenue increase to $3.8 million for Q2 2020, driven primarily by a one-time sale of COVID-19 testers contributing $1.7 million. Gross margin improved to 30.5% from 6.4% year-over-year, while the company achieved an operating income of $0.1 million, compared to a loss of $0.8 million in the same quarter of 2019. Despite positive growth, net income was minimal at $0.01 million, as prior drug sales were affected by the COVID-19 outbreak. Cash and equivalents stood at $1.8 million, up from $1.1 million.
China Pharmaceutical Holdings Limited (NYSE American: CPHI) will hold its Q2 2020 earnings conference call on August 14, 2020, at 8:30 a.m. ET. Participants must register in advance to receive dial-in details. The call will provide insights into the company's financial performance and strategic direction. A replay will be available until August 22, 2020. China Pharma focuses on specialty pharmaceuticals in China, targeting high-incidence conditions such as cardiovascular and infectious diseases, supported by a nationwide distribution network.